Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jens Eckstein
AddedMar 31, 2024
UpdatedMay 31, 2026
Jens Eckstein

Jens Eckstein

Founder, Action Potential Venture Capital

CrunchbaseLinkedIn

Jens Eckstein's Career

Action Potential Venture Capital
Action Potential Venture Capital

Palo Alto, CA, US

Founder
Rapid Micro Biosystems
Rapid Micro Biosystems

Bedford, MA, US

Board Member· Board
Samsara Therapeutics
Samsara Therapeutics

Lewes, DE, US

Board Member· Board
Ascenta Therapeutics
Ascenta Therapeutics

Malvern, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jens Eckstein's Career

Action Potential Venture Capital
Action Potential Venture Capital
Investment FirmInvestment Firm52013Palo Alto, CA, US
Founder
Rapid Micro Biosystems
Rapid Micro Biosystems
Public$377.4M2442006Bedford, MA, US
Board Member· Board

Leadership at Rapid Micro Biosystems

Mark BraganzaMark BraganzaBoard Member
Inese LowensteinInese LowensteinBoard Member
P. Sherrill NeffP. Sherrill NeffBoard Member
Robert SpignesiRobert SpignesiBoard Member
Luc MarengereLuc MarengereBoard Member
Richard S. KollenderRichard S. KollenderBoard Member
Samsara Therapeutics
Samsara Therapeutics
Series A$13.5M362018Lewes, DE, US
Board Member· Board

Leadership at Samsara Therapeutics

Sebastian A. BrunemeierSebastian A. BrunemeierCo-Founder
Oliver KeppOliver KeppCo-Founder
Guido KroemerGuido KroemerCo-Founder

Similar to Samsara Therapeutics

Casma TherapeuticsCasma TherapeuticsCambridge, MA, USBiotechest. 2018Casma TherapeuticsCambridge, MA, US · est. 2018

Casma Therapeutics, a US-based company, designs potent medicines using autophagy for various diseases.

Series C · $154.9M30
PAQ TherapeuticsPAQ TherapeuticsCambridge, MA, USBiotechnology, Therapiesest. 2020PAQ TherapeuticsCambridge, MA, US · est. 2020

PAQ Therapeutics: A biotech leader in autophagy-based therapies for health restoration and disease cure.

Series A · $30M6
CuraSen TherapeuticsCuraSen TherapeuticsSan Carlos, CA, USDrugsest. 2016CuraSen TherapeuticsSan Carlos, CA, US · est. 2016

CuraSen: A biotech firm innovating drugs for CNS and neurodegenerative diseases enhancement.

Series A · $95.9M38
Star TherapeuticsStar TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2018Star TherapeuticsSouth San Francisco, CA, US · est. 2018

Star Therapeutics develops innovative therapies for rare diseases, focusing on novel biology and first-in-class antibody therapeutics.

Series C · $190M48
Ascenta Therapeutics
Ascenta Therapeutics
Public$87.8M752003Malvern, PA, US
Board Member· Board

Leadership at Ascenta Therapeutics

Shaomeng WangShaomeng WangCo-Founder
Eckard WeberEckard WeberBoard Member
Dajun YangDajun YangCo-Founder
Mel SorensenMel SorensenCEO
Lou BockLou BockBoard Member
Marc LippmanMarc LippmanBoard Member

Similar to Ascenta Therapeutics

Ascent TherapeuticsAscent TherapeuticsCambridge, MA, USBiotechest. 2006Ascent TherapeuticsCambridge, MA, US · est. 2006

Cambridge-based Ascent Therapeutics is a leading biotechnology medical organization.

Series A · $19M1
Advanced Cancer TherapeuticsAdvanced Cancer TherapeuticsLouisville, KY, USCancer Therapeuticsest. 2007Advanced Cancer TherapeuticsLouisville, KY, US · est. 2007

US-based Advanced Cancer Therapeutics innovates and commercializes cancer treatments.

Angel · $10.4M8
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Starton TherapeuticsStarton TherapeuticsParamus, NJ, USCancer Therapiesest. 2017Starton TherapeuticsParamus, NJ, US · est. 2017

Starton Therapeutics: A clinical-stage biotech firm innovating cancer care with transdermal technology.

Pre-Seed · $8.5M38

Jens Eckstein's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · Dunamu

People Similar to Jens Eckstein

Sanjit BiswasSanjit BiswasBoard Member · SamsaraColin FosterColin FosterBoard Member · Ontario Bioscience Industry OrganizationKevin StarrKevin StarrCo-Founder · Third Rock VenturesParag GuptaParag GuptaBoard Member · Duetto Research